

About PASI

PASI is derived from skin assessment of the body in four regions: head and neck, arms, trunk (including groin and axillae) and legs (including buttocks). The assessment of the severity of the symptoms erythema, scaling and induration is performed separately for each region. The extent to which each of the four regions of the body is affected by psoriasis is also assessed.

Extent score	Grade	Severity Score	Erythema	Scaling	Induration
0	None	0 – None	No redness	No scaling	No elevation
1	1% to 9%	1 – Mild	Light red	Predominantly fine scaling covering part of the lesion	Slight, but definite elevation; typically edges indistinct or sloped
2	10% to 29%		Red, but not dark red		
3	30% to 49%	3 – Severe	Dark red	Rough, thick scaling covering a large part of the lesion	Marked elevation; typically with hard or sharp edges
4	50% to 69%		Very dark red (changing to purple)		
5	70% to 89%	4 – Very severe			
6	90% to 100%				

Extent			Severity							
Area	Extent score (0-6)	Total extent	Erythema (0-4)	Scaling (0-4)	Induration (0-4)	Total severity	Total severity x total extent			
Head & Neck	<input type="text"/> x 0.1	<input type="text"/>	Head & Neck <input type="text"/>	+	<input type="text"/>	+	<input type="text"/>	=	<input type="text"/>	<input type="text"/>
Arms	<input type="text"/> x 0.2	<input type="text"/>	Arms <input type="text"/>	+	<input type="text"/>	+	<input type="text"/>	=	<input type="text"/>	<input type="text"/>
Trunk	<input type="text"/> x 0.3	<input type="text"/>	Trunk <input type="text"/>	+	<input type="text"/>	+	<input type="text"/>	=	<input type="text"/>	<input type="text"/>
Legs	<input type="text"/> x 0.4	<input type="text"/>	Legs <input type="text"/>	+	<input type="text"/>	+	<input type="text"/>	=	<input type="text"/>	<input type="text"/>
PASI = severity x extent										
<input type="text"/> /72										

Nails should be assessed for any sign of disease. Typical indicators include:

1. Pitting
2. Beau's lines
3. Onycholysis
4. Subungual hyperkeratosis.




Plaque location

Name

Date

Even mild psoriasis can have a serious impact on a patient if it's in a visible area such as the face.¹

This chart enables you to record the location of a patient's plaques at each visit to accurately track their progress.



Reference:

1. NICE Technology Appraisal Guidance TA103. Etanercept and efalizumab for the treatment of adults with psoriasis. July 2006. Available at <http://guidance.nice.org.uk/TA103>. Accessed August 2017.